// App-Quantinova.ai

S291 : C1S-TARGETED INHIBITION OF CLASSICAL COMPLEMENT PATHWAY BY SUTIMLIMAB IN COLD AGGLUTININ DISEASE (CAD): EFFICACY AND SAFETY RESULTS FROM THE RANDOMIZED, PLACEBO (PBO)-CONTROLLED PHASE 3 CADENZA STUDY

Researchers

Presenter

  • Alexander Rth

Principal Investigators

  • Sigbjrn Berentsen

  • Wilma Barcellini

  • Shirley D'Sa

  • Bernd Jilma

  • Marc Michel

  • Ilene C. Weitz

  • Masaki Yamaguchi

  • Jun-ichi Nishimura

  • Josephine Vos

  • Parija Patel

  • Braydon Schaible

  • Xiaoyu Jiang

  • Deepthi Vagge

  • Frank Shafer

  • Michelle Lee

  • Catherine M. Broome

Medical Centers

  • Department of Gastroenterology, Ishikawa Prefectural Central Hospital, Kanazawa, Japan

  • Kinki University, Osaka, Japan

  • Department of Clinical Pharmacology, Medical University of Vienna, Austria

  • MedStar Georgetown University Hospital Washington DC United States

  • Sanofi,Warsaw,Pologne

  • UCLH Centre for Waldenström's Macroglobulinemia and Related Conditions, University College London Hospitals NHS Foundation Trust,London,Vereinigtes Königreich

  • Department of Research and Innovation, Haugesund Hospital, Haugesund, Norway

  • Department of Hematology and Stem Cell Transplantation,University of Duisburg-Essen,Essen,Germany

  • IQVIA, Part of the Sanofi safety team as a contractor,Bangalore,India

  • Department of Hematology,Amsterdam UMC,

  • Sanquin, Amsterdam, the Netherlands

  • IRCCS Ca Granda, Ospedale Maggiore Policlinico, Milano, Italy

  • Sanofi, Cambridge, United States

  • Department of Pediatrics, University of Southern California Keck School of Medicine, Los Angeles, CA

  • Henri Mondor University Hospital, Creteil, France

Locations

  • Japan

  • Austria

  • United States

  • Poland

  • United Kingdom

  • Norway

  • Germany

  • India

  • Netherlands

  • Italy

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Pulmonary/Respiratory Diseases

Disease

  • Chronic obstructive pulmonary disease

Biomarkers

  • Alpha-tubulin N-acetyltransferase 1

Drug/Treatment

  • Mofezolac

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Controlled

Phase

  • III

Study Id's

  • NCT03347422

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved